<DOC>
	<DOCNO>NCT01059903</DOCNO>
	<brief_summary>The major aim study investigate compare drug amount deliver body sequential application two Rotigotine patch two different formulation</brief_summary>
	<brief_title>Study Healthy Volunteers Prove That Two Different Formulations Rotigotine Patches Deliver Equivalent Drug Amount Body</brief_title>
	<detailed_description />
	<mesh_term>N 0437</mesh_term>
	<criteria>Healthy White , male volunteer 18 55 year age ( inclusive ) . BMI 19 28 kg/m^2 ( inclusive ) Previous participation clinical study Rotigotine History current condition epilepsy and/or seizure Known clinically relevant allergy known/suspected clinically relevant drug hypersensitivity History significant skin hypersensitivity adhesives transdermal product recently unresolved contact dermatitis History present condition atopic eczematous dermatitis , psoriasis , and/or active skin disease Clinically relevant abnormality physical examination , ECG , vital sign safety laboratory examination Positive HIV , hepatitis B C test positive alcohol drug test Relevant hepatic renal dysfunction Intake medication might interfere test drug within 2 week prior dose</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Rotigotine</keyword>
	<keyword>NeuproÂ®</keyword>
	<keyword>Transdermal Patch</keyword>
</DOC>